Preparation of PFOB nanoemulsion
To prepare the 20% (v/v) PFOB nanoemulsion, 26 mg of L-α-phosphatidylcholine, 14 mg of cholesterol and 0.4 mg of DSPE-PEG 2000 amine were dissolved in 2 mL of chloroform. A thin film was formed upon the removal of the solvent by vacuum drying. The film was subsequently hydrated with 1.6 mL of ultrapure water and sonicated in a 65C water bath for 1 h. This was followed by the addition of 40 mg of Tween ® 60 and sonication in the 65C water bath for another 25 min. To this mixture, 400 L of PFOB were added, followed by sonication in an ice bath at an amplitude level of 20% for 10 cycles (2 min per cycle) to allow the complete emulsification of PFOB. The resulting nanoemulsion was filtered through a 0.45 μm syringe filter and stored in a sterile glass vial.
PFOB nanoemulsion oxygenation
Preformed PFOB nanoemulsions were oxygenated using an in-house apparatus consisting of an air-tight , BD, USA) was positioned near the top of the glass vial and allowed for gas escape and pressure equalization within the glass vial. Oxygen was bubbled for 3 min at a 3 L/min gas flow.
Upon ending of oxygenation period, needles were immediately removed, sealing the vial under an oxygen-rich atmosphere. Pre-oxygenated PFOB nanoemulsions (OxyPN) were immediately used in subsequent experimental procedures. A schematic representation of the assembly used for oxygenation via O2 bubbling is depicted in Figure S1A .
PFOB nanoemulsion characterization
PFOB nanoemulsions were characterized with respect to particle size distribution, zeta potential, PFOB load and encapsulation efficiency, and oxygenation dynamics as described below.
Particle size and zeta potential distributions
Samples were diluted in ultra-pure grade water (Milli-Q system, Millipore, USA) at a 1:10 dilution and transferred into clear cuvette. Samples were analyzed via dynamic light scattering using the Zetasizer Nano-ZS instrument (Malvern Instruments Ltd., UK). Analyses were performed at 25C with a noninvasive backscatter (NIBS) angle of 173.
Zeta potential distribution was assessed by transferring the diluted sample into folded capillary cells (), which were subsequently analyzed via laser doppler anemometry using the Zetasizer Nano-ZS instrument (Malvern Instruments Ltd., UK) at 25C.
PFOB load and encapsulation efficiency
PFOB load and encapsulation efficiency were determined using a gravimetric method. 250 L of each formulation was transferred into a centrifuge tube (n=6). Around 100 L of chloroform was added to the tube and vigorously mixed for 1 h to ensure the solubilization of all formulation's components besides PFOB, which is insoluble and immiscible in chloroform. Tubes were centrifuged for 1 h (relative centrifugal force = 2655 g; 20C). A tri-phasic dispersion was formed where, based on density, the top layer was the aqueous supernatant (1.0 g/cm 3 ), the middle layer was chloroform with phospholipids and cholesterol dissolved in it (~1.49 g/cm 3 ), and the bottom one was pure PFOB (1.93 g/cm 3 ). The bottom layer was transferred to a clean tube and weighed for the absolute PFOB content. PFOB load was determined as the volume of PFOB per unit volume of nanoemulsion, and encapsulation efficiency was calculated as the percentage amount of PFOB present in the formulation with respect to the original amount added during manufacturing.
Oxygenation dynamics characterization
Oxygenation dynamics were assessed via AL300 oxygen sensor probe attached to the NeoFox-GT fluorometer (Ocean Optics, USA). PFOB nanoemulsion (2 mL) was added to a closed vial and assembled for oxygenation as described in "PFOB nanoemulsion oxygenation" subsection. A third needle was added to the system through which the AL300 oxygen sensor probe passed through and reached the formulation on the bottom of the vial ( Figure S1B ). Oxygenation was performed by bubbling pure O 2 into glass vials containing the PFOB nanoemulsion for up to 3 min. Oxygen levels were allowed to stabilize under hyperoxic environment (closed air-tight vial) for 5 min. Next, in vitro oxygen release was simulated upon unsealing the air-tight vial for atmospheric re-equilibration.
The responsiveness of Image-iT TM hypoxia optical probe was also verified upon its addition to non- fetal bovine serum, 1% penicillin/streptomycin, and 1% L-glutamine in a 37C incubator supplied with 5% CO 2 . A549 cells were conditioned into a hypoxic state by incubating the cells in a sealed hypoxic chamber (MIC-101, Billupus-Rothenberg Inc., USA) containing a gas mixture of 1% O 2 and 5% CO 2 balanced with 94% N 2 at 37C for 24 h. A549 cells were conditioned into a normoxic state by incubating the cells in 20% O 2 and 5% CO 2 balanced with 94% N 2 at 37C for 24 h.
In vitro A549 cytotoxicity
Hypoxic A549 cells were subsequently treated with 10, 30 or 60 μM CPT followed by incubation for 24 h in ambient air (21% O 2 ), under carbogen (hyperoxic environment) for 3 h followed by 21 h incubation under ambient air, or with pre-oxygenated 0.4% v/v PFOB nanoemulsion in DMEM with incubation under carbogen as above. Cell viability was assessed by adding a solution containing 10 μL of CCK-8
and 100 μL of fresh cell culture medium to each well after incubation. Cells were then incubated for an additional 2 h at 37C under 5% CO 2 . Finally, absorbance values were measured at 450 nm using a microplate reader. Cells treated with saline and cultured under similar conditions were used as negative controls for each group.
Animals and human lung cancer xenograft tumor model
Severe combined immunodeficiency (SCID) mice were purchased from the Jackson Laboratory To assess the impact of tumor oxygenation from circulating PN and PN accumulated in tumor tissue, mice were administered with OxyPN or saline and 24 h later the animals received an intratumoral dose of Image-iT TM hypoxia reagent. Fluorescence signal was allowed to stabilize for 3 h and background signal was measured (27 h post initial treatment). Animals were allowed to breath carbogen (95% O 2 and 5% CO 2 ) for 1 h and re-imaged to assess the oxygenation effect attributed to lingering PN in blood circulation at 28 hours post injection.
Ex vivo optical imaging of apoptosis in tumors
Tumor apoptosis was evaluated in vivo by comparing three groups of tumor-bearing SCID mice (n=3):
(1) intravenous administration of 5 mg/kg of CPT with ambient air breathing for 3 h; (2) 
In vivo antitumor efficacy & ex vivo apoptosis staining
Tumor-bearing mice with average tumor sizes of 60-75 mm 3 were randomly assigned to 5 different groups (n=4) for subsequent treatment. Mice were administered intravenously with 50 μL of (1) At the end of the study, animals were euthanized, and tumors were harvested. Tumors were blocked in paraffin and sectioned into 5 µm-thick slices. Slices were stained with hematoxylin and eosin (H&E).
Terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) staining was also performed as means to detect DNA fragmentation for apoptosis assessment. Representative slices of each group were analyzed under an optical microscope and the number of apoptotic cells as a percentage of total cells in the HPF was determined (n=4, 10 HPF/tumor).
In vivo circulation half-life
Mice were administered intravenously with 50 μL of OxyPN and dynamic changes in X-ray attenuation were monitored using the eXplore CT120 system (GE Healthcare, USA) at an 80 kV accelerating voltage. X-ray attenuation was calculated as a function of Hounsfield Units (HU) at the left ventricle.
In vivo tumor accumulation
PN was manufactured with the addition of DiR' dye (Dil C 18 (7); Thermo Fisher Scientific, USA) to the lipid solution prior to organic solvent evaporation. Formulation was prepared as described in the "Preparation of PFOB nanoemulsion" subsection. Tumor-bearing SCID mice (average tumor size = 75 mm 3 ) were dosed with 50 L of DiR'-loaded PN intravenously (tail vein injection) and fluorescence signals were monitored at 1, 3, 6 and 24 h post-administration. Data collection was performed using the IVIS  Lumina LT Series III pre-clinical imaging system (Perkin Elmer, Inc., USA) at excitation and emission wavelengths of 750 and 780 nm, respectively.
Histopathological evaluation of toxicity
At the end of the efficacy study, organs (lungs, spleens, hearts, livers, and kidneys) were harvested, blocked in paraffin and sectioned into 5 µm-thick slices, followed by H&E staining. An additional tumor-bearing mouse group was treated with a high dose of CPT (2 mg/kg) to be used as positive control, where toxicity is expected to occur. Histopathological analysis was performed at the
Connecticut Veterinary Medical Diagnostic Laboratory by a single-blinded Doctor of Veterinary
Medicine.
Statistical analysis
To statistically demonstrate significant differences between groups in related studies, one-way or twoway analysis of variance (ANOVA) tests were performed. Post-hoc analysis was done using Tukey's Multiple Comparison test, unless stated otherwise. Statistical tests were performed using Prism 8.0 software (GraphPad Software Inc., USA).
SUPPLEMENTARY RESULTS AND DISCUSSION

PFOB nanoemulsion formation
PFOB nanoemulsions were prepared yielding homogeneous opaque formulations. Upon PFOB addition to an aqueous dispersion containing phospholipids, it does not mix. However, inputting high sonic energy promotes the dispersion of PFOB droplets in the continuous aqueous phase. Due to the amphiphilic behavior of phosphatidylcholine (surfactant used in our formulation), it interacts with the PFOB droplets, coating their surface, while still interacting with the aqueous environment -thus stabilizing the PFOB nanodroplets.
In vitro PFOB nanoemulsion oxygenation
Upon oxygenation for 3 minutes with oxygen bubbling (Figure 1E ), dissolved oxygen content in saline increased from 15.1  2.4 ppm to 136.4  48.2 ppm (p<0.0001), whereas PN showed an increase from 73.7  8.6 ppm to 325.2  86.4 ppm (p<0.0001). Oxygen bubbling led to a supersaturated state with respect to the dissolved oxygen content. As soon as oxygen bubbling ceased, the oxygen content quickly reduces. During the period of oxygenation, there is a clear increase in oxygen content in the sample. The high variability observed during oxygen bubbling is likely due to the interference of the bubbles on the fluorometer signal. Upon cessation of bubbling, saline and PN showed a high variation in readings from the fluorometer due to the hyperoxic environment. PN showed enhanced capability of carrying oxygen when compared with saline, leading to a comparative 2.5-fold increase in dissolved oxygen (p<0.0001).
The supersaturated oxygen levels are sustained under hyperoxic environment, translating into a metastable condition. Upon opening of the air-tight vial, the hyperoxic headspace quickly equilibrates with the room air (~21% O 2 ) and promotes oxygen release from the supersaturated liquid, quickly donating oxygen to the atmosphere following Henry's gas law ( Figure S1C ). The oxygen contents rapidly decreased for both samples, within a 5 minutes interval. The rate of decrease is apparently similar for both systems. were made with BioRender.
Half-Life of PFOB nanoemulsion
The circulation time of the PFOB nanoemulsion is of upmost importance considering it supplies supplementary oxygen only while in circulation. Additionally, PFOB shows high X-ray attenuation, and therefore it can be directly tracked in vivo using X-ray Computed Tomography (CT). Animals were injected with PFOB intravenously (tail vein injection; 50 L/mouse) and the X-ray attenuation as measured in 4 distinct anatomies of interest: right ventricle, left ventricle, aorta and inferior vena cava. 
Reduced CPT off-target toxicity following co-treatment with PFOB nanoemulsion
General toxicity upon treatment was investigated by monitoring the mice's weight variations throughout the efficacy study. Figure S4 displays relative growth curves for all treated groups. Saline group displayed a growth curve consistent with the natural growth of the animals. This effect was also verified for the OxyPN+O 2 group showcasing the apparent safety of the formulation tested. CPT, CPT+O 2 and CPT+OxyPN+O 2 groups showed reduction in growth rate with respect to saline control, which was due to the known toxicity of cisplatin.
On the histopathological analysis, no signs of oxygen-related toxicity (e.g. lung injury) were observed.
No other signs of toxicity were observed in other organs as neither CPT nor the PFOB nanoemulsion caused histological damage to those tissues ( Figure S5 ). These findings sustain the hypothesis that the PFOB nanoemulsion itself did not imply in significant in vivo toxicity. Moreover, the reduction in animal growth rate observed in vivo was associated solely to the administration of cisplatin and it is an anticipated side-effect of chemotherapy. 
